June 7, 2017
CHARISMA supports efforts to: increase women’s agency to safely use ARV-based HIV prevention, to engage male partners in HIV prevention, and to overcome harmful gender norms and reduce intimate partner violence (IPV). Clinic- and community-based interventions continue. Intervention evaluations and reporting planned. Clinic- and community-based interventions continue. CHARISMA is piloting its clinic-based intervention as part… Read more »
June 7, 2017
POWER develops cost-effective and scalable models for implementation of ARV-based HIV prevention products for women. Mental models community surveys completed. Training for POWER’s PrEP delivery cohort completed in Cape Town, Johannesburg, and Kisumu. Site activation scheduled. My PrEP decision support tool undergoes cognitive testing. Mental models community surveys completed. As part of the mental models… Read more »
June 7, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Oral PrEP modeling completed. Collaboration in Kenya continues. Resources being developed for training and M&E. Genital swabs testing begins and assay development is underway. In collaboration with… Read more »
June 7, 2017
EMOTION “Project EMOTION: Creating HIV Prevention Products that Fit into Women’s Lives.” USAID Global Health Newsletter. May 2017. GEMS “Future technologies for monitoring HIV drug resistance and cure.” Current Opinion in HIV & AIDS. March 2017, Vol 12, Issue 2, p 182-189.
June 7, 2017
EMOTION increases uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy. Project VOGUE underway. Project VOGUE underway. EMOTION is currently preparing for Project VOGUE, a socio-behavioral study comparing the human-centered design (HCD) branded experience and product to unbranded product and… Read more »
February 27, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Initial oral PrEP modeling completed. Collaboration in Kenya and Namibia continues. Genital swabs testing begins and assay development is underway. GEMS has collaborated with Partners PrEP and… Read more »
February 27, 2017
OPTIONS presented two posters at CROI 2017 in February focused on modeling work in Kenya: “Cost-effectiveness of pre-exposure prophylaxis across counties in Western Kenya” and “HIV transmission in generalized, concentrated, and mixed epidemics in Western Kenya.” GEMS also presented the poster, “Does the E138A Mutation in ASPIRE Seroconverters Affect Susceptibility to Dapivirine?”
February 27, 2017
EMOTION increases uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy. Pilot messaging study completed. Socio-behavioral study underway. Pilot messaging study completed. Project Siyavala, the pilot messaging study, builds on findings from Project Kalahari, which focused on the “End User Journey”… Read more »